Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.54 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021477 | 0.86 | PTGS2 (0.67) | PTGS2PTGS1CA1CA2PTGER1 | |
| SCHEMBL3026195 | 0.85 | PTGS2 (0.52) | PTGS2PTGS1CA1CA2CA5A | |
| SCHEMBL3033871 | 0.84 | PTGS2 (0.58) | PTGS2PTGS1CA1CA2CA5A | |
| SCHEMBL3025180 | 0.83 | PTGS2 (0.68) | PTGS2PTGS1CA1CA2PTGER1 | |
| SCHEMBL7210840 | 0.83 | PTGS2 (0.76) | PTGS2PTGS1CA1CA2CA5A | |
| SCHEMBL7216218 | 0.80 | PTGS2 (0.76) | PTGS2PTGS1CA1CA2PTGER1 | |
| SCHEMBL5314020 | 0.78 | CHRNA7 (0.60) | PTGS2PTGS1CA1CA2CA5A | |
| SCHEMBL7210689 | 0.78 | PTGS2 (0.77) | PTGS2PTGS1CA1CA2CHRNA7 | |
| SCHEMBL7215363 | 0.78 | PTGS2 (0.59) | PTGS2PTGS1CA1CA2PTGER1 | |
| SCHEMBL3021555 | 0.78 | PTGS2 (0.77) | PTGS2PTGS1CA1CA2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609713-B2 | Pyrrole derivatives and their methods of use | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-7741364-B2 | Neuronal nicotinic acetylcholine receptor modulators; such as ethyl 1-[4-(aminosulfonyl)phenyl]-5-(4-bromophenyl)-2-methyl-1H-pyrrole-3-carboxylate | ABBOTT LABORATORIES (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | PYCR1, PPOX, DHPS | PTGS2 69/4885PTGS1 79/4885CA1 2955/4885 |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | PYCR1, PPOX, DHPS | PTGS2 69/4885PTGS1 79/4885CA1 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.